You are here

  • Home
  • Archive
  • Volume 10, Issue 7
  • TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

 

Online download statistics by month:

Online download statistics by month: July 2022 to July 2025

AbstractFullPdf
Jul 2022861881337
Aug 2022392395145
Sep 202225826896
Oct 2022288289115
Nov 202219219987
Dec 202218418493
Jan 202317818070
Feb 202322823290
Mar 202320320688
Apr 202316416679
May 202320620689
Jun 202318318350
Jul 202314214476
Aug 202318118193
Sep 202311011059
Oct 202319719752
Nov 202315615752
Dec 202310610740
Jan 2024868754
Feb 202410710731
Mar 202412612887
Apr 202413413590
May 202412912953
Jun 202417117057
Jul 202418118273
Aug 202414614547
Sep 202414814955
Oct 202418418673
Nov 202415615965
Dec 202413413773
Jan 202515415873
Feb 2025969643
Mar 2025142142114
Apr 202515915971
May 202512412468
Jun 202511211549
Jul 2025110
Total671967942887